319 results
Keyword HCT Remove keyword
-
List item
Opinion/decision on a Paediatric investigation plan (PIP): Imprida HCT, valsartan, hydrochlorothiazide, Amlodipine besilate
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Cardiovascular diseases
PIP number: EMEA-000399-PIP01-08, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 27/01/2009, Last updated: 06/03/2009, Compliance check: XKey facts Imprida HCT valsartan hydrochlorothiazide … hydrochlorothiazide, (Imprida HCT), (EMEA-000399-PIP01-08) in … EMEA/24175/2009 Generic Imprida HCT: EPAR Imprida … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Dafiro HCT, valsartan, hydrochlorothiazide, Amlodipine besilate
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Cardiovascular diseases
PIP number: EMEA-000398-PIP01-08, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 27/01/2009, Last updated: 06/03/2009, Compliance check: XKey facts Dafiro HCT valsartan hydrochlorothiazide … hydrochlorothiazide, (Dafiro HCT), (EMEA-000398-PIP01-08) in … EMEA/24169/2009 Generic Dafiro HCT: EPAR Angiotensin-II-receptor … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Copalia HCT, valsartan, hydrochlorothiazide, Amlodipine besilate
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Cardiovascular diseases
PIP number: EMEA-000397-PIP01-08, Route(s) of administration: Oral use, Pharmaceutical form(s): Film-coated tablet
Decision date: 27/01/2009, Last updated: 06/03/2009, Compliance check: XKey facts Copalia HCT valsartan hydrochlorothiazide … hydrochlorothiazide, (Copalia HCT), (EMEA-000397-PIP01-08) in … EMEA/24151/2009 Generic Copalia HCT: EPAR Angiotensin-II-receptor … -
List item
Human medicine European public assessment report (EPAR): Actelsar HCT
telmisartan, hydrochlorothiazide, Essential Hypertension
Date of authorisation: 13/03/2013,
, Revision: 12, Authorised, Last updated: 27/01/2021
Actelsar HCT Essential Hypertension … report (EPAR) for Actelsar HCT. It explains how the Agency … advice on how to use Actelsar HCT. For practical information … -
List item
Human medicine European public assessment report (EPAR): Rasilez HCT
aliskiren, hydrochlorothiazide, Hypertension
Date of authorisation: 16/01/2009, Revision: 17, Authorised, Last updated: 26/08/2020Rasilez HCT Hypertension … aliskirenhydrochlorothiazide Overview Rasilez HCT is a medicine used to treat … hypertension can be found. Rasilez HCT is used in patients whose … -
List item
Human medicine European public assessment report (EPAR): Sprimeo HCT
aliskiren, hydrochlorothiazide, Hypertension
Date of authorisation: 23/06/2011, Withdrawn, Last updated: 28/08/2012Sprimeo HCT Hypertension … authorisation for Sprimeo HCT has been withdrawn at the … Summary documents Sprimeo HCT : EPAR - Summary for the … -
List item
Human medicine European public assessment report (EPAR): Riprazo HCT
aliskiren, hydrochlorothiazide, Hypertension
Date of authorisation: 13/04/2011, Withdrawn, Last updated: 20/09/2012Riprazo HCT Hypertension … authorisation for Riprazo HCT has been withdrawn at the … Summary documents Riprazo HCT : EPAR - Summary for the … -
List item
Human medicine European public assessment report (EPAR): Copalia HCT
amlodipine, valsartan, hydrochlorothiazide, Hypertension
Date of authorisation: 03/11/2009, Revision: 17, Authorised, Last updated: 24/11/2020Copalia HCT Hypertension … report (EPAR) for Copalia HCT. It explains how the Committee … conditions of use for Copalia HCT. If you need more information … -
List item
Human medicine European public assessment report (EPAR): Exforge HCT
valsartan, hydrochlorothiazide, Amlodipine besilate, Hypertension
Date of authorisation: 15/10/2009, Revision: 17, Authorised, Last updated: 07/07/2020Exforge HCT Hypertension … report (EPAR) for Exforge HCT. It explains how the Committee … conditions of use for Exforge HCT. What is Exforge HCT? Exforge HCT is a medicine that contains … -
List item
Human medicine European public assessment report (EPAR): Dafiro HCT
valsartan, hydrochlorothiazide, Amlodipine besilate, Hypertension
Date of authorisation: 03/11/2009, Revision: 19, Authorised, Last updated: 07/07/2020Dafiro HCT Hypertension … the EPAR). What is Dafiro HCT? Dafiro HCT is a medicine that contains … 10/320/25 mg. What is Dafiro HCT used for? Dafiro HCT is used to treat essential … -
List item
Human medicine European public assessment report (EPAR): Imprida HCT
amlodipine, valsartan, hydrochlorothiazide, Hypertension
Date of authorisation: 15/10/2009, Revision: 3, Withdrawn, Last updated: 22/10/2012Imprida HCT Hypertension … authorisation for Imprida HCT has lapsed because it has … Summary documents Imprida HCT : EPAR - Summary for the … -
List item
Referral: Renin-angiotensin-system (RAS)-acting agents
captopril, imidapril, zofenopril, candesartan, delapril, telmisartan, aliskiren, moexipril, enalapril, valsartan, fosinopril, irbesartan, perindopril, quinapril, ramipril, eprosartan, olmesartan, trandolapril, losartan, azilsartan, lisinopril, spirapril, benazepril, cilazapril, associated names: Tolucombi, Telmisartan Teva, Telmisartan Teva Pharma, Tolura, Onduarp, Twynsta, Actelsar HCT, Kinzalkomb, MicardisPlus, PritorPlus, Copalia HCT, Dafiro HCT, Exforge HCT, Rasilamlo, Rasilez, Rasilez HCT, Rasitrio, Edarbi, Ipreziv, Aprovel, Ifirmasta (previously Irbesartan Krka), Irbesartan Teva, Irbesartan Zentiva (previously Irbesartan Winthrop), Karvea, Sabervel, CoAprovel, Ifirmacombi, Irbesartan/Hydrochlorothiazide Teva, Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop), Karvezide, Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG), Micardis, Pritor, Telmisartan Actavis, Article 31 referrals
Status: European Commission final decision, opinion/position date: 22/05/2014, EC decision date: 04/09/2014, Last updated: 08/10/2014Pharma Tolura Onduarp Twynsta Actelsar HCT Kinzalkomb MicardisPlus PritorPlus Copalia … disPlus PritorPlus Copalia HCT Dafiro HCT Exforge HCT Rasilamlo Rasilez Rasilez … -
List item
Referral: Angiotensin-II-receptor antagonists (sartans) containing a tetrazole group
valsartan, candesartan, irbesartan, losartan, olmesartan, associated names: Karvezide, Karvea, Irbesartan/Hydrochlorothiazide Teva, Irbesartan Zentiva (previously Irbesartan Winthrop), Irbesartan Teva, Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop), Ifirmasta (previously Irbesartan Krka), Ifirmacombi, Aprovel, Neparvis, Exforge, Exforge HCT, Entresto, Dafiro HCT, Dafiro, Copalia HCT, Copalia, Amlodipine / Valsartan Mylan , CoAprovel, Article 31 referrals
Status: European Commission final decision, opinion/position date: 12/11/2020, EC decision date: 19/02/2021, Last updated: 19/03/2021Krka) Ifirmacombi Aprovel Neparvis Exforge Exforge HCT Entresto Dafiro HCT Dafiro Copalia HCT Copalia Amlodipine / Valsartan … -
List item
Referral: Tritazide
ramipril, hydrochlorothiazide, Article 30 referrals
Status: European Commission final decision, opinion/position date: 18/12/2008, EC decision date: 06/03/2009, Last updated: 14/04/2009passageways. Hydrochlorothiazide (HCTZ) is a diuretic. It works … Plus, Ramilich Comp, Tritace HCT, Triatec HCT, Ramipril e Idrocloritiazide … Forte, Vesdil Plus, Ramipril HCT Zentiva, Unipril Diur, Idroquark … -
List item
Press release: European Medicines Agency starts review of aliskiren-containing medicines following termination of ALTITUDE study
CHMP, Last updated: 22/12/2011Rasilamlo, Rasilez, Rasilez HCT, Rasitrio, Riprazo, Riprazo HCT, Sprimeo, Sprimeo HCT. Some of these medicines (Rasilamlo … Rasilamlo, Rasilez, Rasilez HCT, Rasitrio, Riprazo, Riprazo HCT, Sprimeo, Sprimeo HCT. Some of these medicines … -
List item
Press release: European Medicines Agency recommends new contraindications and warnings for aliskiren-containing medicines
CHMP, Last updated: 17/02/2012Rasilamlo, Rasilez, Rasilez HCT, Rasitrio, Riprazo, Riprazo HCT, Sprimeo and Sprimeo HCT. Some of these medicines (Rasilamlo … Rasilamlo, Rasilez, Rasilez HCT, Rasitrio, Riprazo, Riprazo HCT, Sprimeo and Sprimeo HCT. Some of these medicines … -
List item
News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2013
PRAC, Last updated: 17/05/2013PRAC recommendation Actelsar HCT: EPAR Aprovel: EPAR CoAprovel … EPAR Copalia: EPAR Copalia HCT: EPAR Dafiro: EPAR Dafiro HCT: EPAR Edarbi: EPAR Exforge … EPAR Exforge: EPAR Exforge HCT: EPAR Ifirmacombi: EPAR Ifirmasta … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 October 2011
CHMP, Last updated: 21/10/2011EPAR Copalia: EPAR Copalia HCT: EPAR Dafiro: EPAR Dafiro HCT: EPAR Exforge: EPAR Exforge HCT: EPAR Glubrava: EPAR Glustin … -
List item
Press release: European Medicines Agency concludes that benefit-risk balance of angiotensin-II-receptor antagonists remains positive
CHMP, Last updated: 20/10/2011EPAR Copalia: EPAR Copalia HCT: EPAR Dafiro: EPAR Dafiro HCT: EPAR Exforge: EPAR Exforge HCT: EPAR Ifirmacombi: EPAR Ifirmasta … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 February 2012
CHMP, Last updated: 17/02/2012Sprimeo, Rasilamlo, Rasilez HCT, Riprazo HCT, Sprimeo HCT, Rasitrio aliskiren Novartis … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2013
CHMP, Last updated: 28/06/2013Copalia HCT INN amlodipine / valsartan … -
List item
Referral: Diovan Comp
valsartan, hydrochlorothiazide, Article 30 referrals
Status: European Commission final decision, opinion/position date: 19/03/2009, EC decision date: 26/05/2009, Last updated: 11/06/2009Co-Tareg, Cotareg, Diovan HCT, Kalpress Plus, Levetix, Mitten … Co-Tareg, Cotareg, Diovan HCT, Kalpress Plus, Levetix … -
List item
Press release: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 January 2011
CHMP, Last updated: 21/01/2011Riprazo HCT … authorisation for Riprazo HCT (aliskiren/hydrochlorothiazide … hypertension. The review for Riprazo HCT began on 21 November 2010 … -
List item
Press release: European Medicines Agency recommends new contraindication and warning for Rasilez and other aliskiren medicines
Last updated: 19/02/2009hydrochlorothiazide as Rasilez HCT. The Product Information for … hydrochlorothiazide as Rasilez HCT. The Product Information … -
List item
National expert: Fernando Mendez Hermida, Spanish Agency of Medicines and Medical Devices (updated)
- Declaration of interests - 79.79 KB | PDF
- Curriculum Vitae - 30.71 KB | PDF